stockportfolio.pro
Stocks / ANAB vs MBX
ANAB vs MBX
AnaptysBio, Inc. and MBX Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AnaptysBio, Inc. (ANAB) | MBX Biosciences, Inc. (MBX) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $234.60M | $0 |
| Net income (latest FY) | $-13.23M | $-86.97M |
| Revenue growth (5y CAGR) | 25.6% | — |
| Net margin | -5.6% | — |
| Return on equity | -35.6% | -23.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANAB — free Open MBX — freeFrequently asked questions
Which is bigger, ANAB or MBX?
MBX Biosciences, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, ANAB or MBX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.